Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial

Shaji K. Kumar, Suzanne R. Hayman, Francis K. Buadi, Vivek Roy, Martha Q. Lacy, Morie A. Gertz, Jacob Allred, Kristina M. Laumann, Leif P. Bergsagel, David Dingli, Joseph R. Mikhael, Craig B. Reeder, A. Keith Stewart, Steven R. Zeldenrust, Philip R. Greipp, John A. Lust, Rafael Fonseca, Stephen J. Russell, S. Vincent Rajkumar, Angela Dispenzieri